Classement en actions
#14023
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to... Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Capitalisation boursière
$442.29M
Changement (1 jour)
-1.13%
Changement (1 an)
769.01%
Échange Q32 Bio Inc. (QTTB)
Revenus pour Q32 Bio Inc. (QTTB)
Revenus en Sep 2026 TTM : 0
Selon les derniers rapports financiers de Q32 Bio Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Q32 Bio Inc. de 2026 à 2026
Revenus à la fin de chaque année
| Année |
Revenus |
Changez |
|
Pas assez de données pour les dates fournies. |
Revenus d’entreprises similaires ou concurrentes
| Entreprise |
Revenus |
Différence de revenus |
Pays |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
$15.74B |
-
|
AU
|
|
|
$2.23B |
-
|
US
|
|
|
- |
-
|
CH
|
